Vanguard Group Inc. Boosts Stock Holdings in Privia Health Group, Inc. $PRVA

Vanguard Group Inc. boosted its holdings in shares of Privia Health Group, Inc. (NASDAQ:PRVA) by 5.3% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 12,098,933 shares of the company’s stock after acquiring an additional 607,447 shares during the quarter. Vanguard Group Inc. owned 0.10% of Privia Health Group worth $301,263,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in PRVA. Royal Bank of Canada lifted its position in shares of Privia Health Group by 63.5% during the first quarter. Royal Bank of Canada now owns 245,633 shares of the company’s stock valued at $5,514,000 after buying an additional 95,371 shares during the last quarter. AQR Capital Management LLC boosted its stake in Privia Health Group by 24.7% in the first quarter. AQR Capital Management LLC now owns 40,781 shares of the company’s stock valued at $916,000 after acquiring an additional 8,068 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Privia Health Group by 3.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 118,764 shares of the company’s stock worth $2,666,000 after purchasing an additional 3,714 shares during the last quarter. Intech Investment Management LLC grew its holdings in Privia Health Group by 55.1% in the first quarter. Intech Investment Management LLC now owns 56,553 shares of the company’s stock worth $1,270,000 after purchasing an additional 20,082 shares during the last quarter. Finally, Acadian Asset Management LLC purchased a new stake in Privia Health Group in the first quarter valued at about $154,000. Institutional investors own 94.48% of the company’s stock.

Key Privia Health Group News

Here are the key news stories impacting Privia Health Group this week:

• Positive Sentiment: Q4 and full‑year 2025 results beat expectations and management delivered bullish 2026 guidance — revenue, EPS and adjusted EBITDA came in above guidance with adjusted EBITDA up strongly Y/Y and management guiding ~20% adjusted EBITDA growth (midpoint) and expansion to 24 states. This is the main fundamental driver supporting upside. GlobeNewswire
• Positive Sentiment: Analyst optimism: Canaccord recently raised its PRVA price target (to $35) and the mean analyst target implies material upside; several outlets highlight a consensus uplift in price targets — supportive for further analyst‑driven buying. Canaccord / Benzinga coverage
• Positive Sentiment: Company guidance emphasizes converting ~80% of adjusted EBITDA to free cash flow and ending 2026 with ~ $600M cash, plus no debt — balance‑sheet strength that can underwrite organic growth or M&A. MSN / coverage of guidance
• Neutral Sentiment: Supporting disclosure and materials: transcript and slide deck from the earnings call are available for deeper read — useful for modeling cadence of revenue/EBITDA conversions and provider growth assumptions. Earnings transcript (Yahoo)
• Negative Sentiment: Offset risks: large non‑cash stock‑based compensation ($71.1M in 2025), management’s note that forward non‑GAAP measures aren’t reconciled to GAAP (adding forecasting uncertainty), and disclosure of insider sales in recent months — items that can temper investor enthusiasm. QuiverQuant / release summary
• Negative Sentiment: Valuation and market action: PRVA trades at a high trailing P/E and the stock is seeing elevated volume today — likely profit‑taking or rotation despite the beat. That dynamic, plus at least one lower analyst target in the mix historically, helps explain short‑term downward pressure.

Privia Health Group Price Performance

Privia Health Group stock opened at $23.75 on Friday. Privia Health Group, Inc. has a 12 month low of $18.77 and a 12 month high of $26.51. The stock has a market capitalization of $2.92 billion, a PE ratio of 139.71, a price-to-earnings-growth ratio of 1.72 and a beta of 0.83. The business has a 50 day simple moving average of $23.07 and a 200-day simple moving average of $23.46.

Privia Health Group (NASDAQ:PRVA) last announced its earnings results on Thursday, February 26th. The company reported $0.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.21. The company had revenue of $541.17 million for the quarter, compared to analysts’ expectations of $516.61 million. Privia Health Group had a net margin of 1.08% and a return on equity of 3.12%. The firm’s quarterly revenue was up 17.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.21 EPS. On average, equities research analysts anticipate that Privia Health Group, Inc. will post 0.14 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on PRVA. Truist Financial restated a “buy” rating and issued a $31.00 target price (up from $30.00) on shares of Privia Health Group in a research note on Monday, November 10th. Weiss Ratings restated a “hold (c)” rating on shares of Privia Health Group in a research note on Monday, December 29th. Barclays raised their target price on shares of Privia Health Group from $22.00 to $23.00 and gave the stock an “equal weight” rating in a report on Monday, November 10th. Canaccord Genuity Group upped their price target on shares of Privia Health Group from $34.00 to $35.00 and gave the company a “buy” rating in a report on Friday. Finally, Piper Sandler reissued an “overweight” rating and issued a $36.00 price objective on shares of Privia Health Group in a report on Thursday. Thirteen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $30.79.

Insider Activity at Privia Health Group

In other news, CFO David Mountcastle sold 23,887 shares of the business’s stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $25.03, for a total transaction of $597,891.61. Following the completion of the transaction, the chief financial officer directly owned 172,909 shares of the company’s stock, valued at approximately $4,327,912.27. The trade was a 12.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Matthew Shawn Morris sold 13,647 shares of the business’s stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $25.01, for a total transaction of $341,311.47. Following the transaction, the director owned 68,188 shares of the company’s stock, valued at $1,705,381.88. This trade represents a 16.68% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 10.70% of the company’s stock.

Privia Health Group Company Profile

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.